C-Ray Therapeutics Secures Radiopharmaceutical Production License in China, Bolstering CRDMO Capabilities
核心洞察
C-Ray Therapeutics (搜索) has officially obtained a Radiopharmaceutical Production License following on-site inspections by Sichuan provincial and national regulatory authorities.
The certification was granted under China's updated regulatory framework for outsourced pharmaceutical manufacturing with strengthened quality management and inspection standards.
The license confirms the company's compliance systems, on-site execution capability, and reliable supply performance meet regulatory expectations for radiopharmaceutical contract manufacturing.
C-Ray Therapeutics (搜索) (Chengdu) Co., Ltd. has officially obtained a Radiopharmaceutical Production License, the company announced, following the successful completion of on-site inspections conducted by a panel of experts from the Sichuan Provincial Center for Drug Evaluation and the National Defense Science and Industry Administration. The milestone, finalized on June 23, 2026, positions the company to strengthen its contract research, development, and manufacturing organization (CRDMO) capabilities within China's rapidly evolving radiopharmaceutical sector.
The certification was granted under China's updated regulatory framework for outsourced pharmaceutical manufacturing, which has introduced strengthened requirements for quality management systems, responsibility allocation, and on-site inspection standards. The approval confirms that C-Ray Therapeutics (搜索)' compliance system, on-site execution capability, and reliable supply performance in radiopharmaceutical contract manufacturing meet current regulatory expectations.
Regulatory Significance and Operational Demands
Radiopharmaceutical manufacturing presents unique challenges distinct from conventional pharmaceutical production. The field is characterized by short production cycles, stringent quality requirements, and complex supply chain coordination — factors that place high demands on the compliance systems and operational capabilities of contract development and manufacturing organizations. The successful licensure signals that C-Ray Therapeutics (搜索) has demonstrated the infrastructure and procedural rigor necessary to operate within these constraints.
The approval also strengthens the foundation for future regulatory submissions and the commercialization of partnered programs, according to the company, providing a clearer pathway for clients seeking to advance radiopharmaceutical candidates through development and toward market authorization under China's Marketing Authorization Holder (MAH) framework.
Operational Track Record
Guided by its stated philosophy of "high quality, high efficiency, and first-time-right execution," C-Ray Therapeutics (搜索) has established a modern cGMP-compliant manufacturing facility operated by an experienced technical and regulatory team. To date, the company reports having delivered more than 100 CRDMO projects, covering the full development lifecycle from early-stage research through to commercial supply — a breadth of experience that underscores its role in the radiopharmaceutical outsourcing landscape.